Emmaus gains marketing authorisation for sickle cell treatment in Oman

Emmaus Life Sciences has received marketing authorisation for Endari (L-glutamine oral powder) in Oman for sickle cell disease.

Jul 15, 2023 - 20:00

Emmaus gains marketing authorisation for sickle cell treatment in Oman

Emmaus Life Sciences has received marketing authorisation for Endari (L-glutamine oral powder) in Oman for sickle cell disease.

Read the original article

Tags:

Previous Article

Health Canada approves AstraZeneca-Merck’s prostate cancer therapy

Incyte’s Opzelura Meets Primary Endpoint in Eczema Trial, but Safety Concerns Pe...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement

STAT+: U.S. Supreme Court to review controversial Purdu...

Dec 1, 2023

AlphaFold developers and eye scan inventors among Lasker Award winners for 2023

AlphaFold developers and eye scan inventors among Laske...

Sep 22, 2023

FDA grants fast track status to Innovent’s IBI363 for melanoma

FDA grants fast track status to Innovent’s IBI363 for m...

Sep 4, 2024